Abstract

P‐glycoprotein (P‐gp) is a cell membrane—associated protein that transports a variety of drug substrates. Although P‐gp has been studied extensively as a mediator of multidrug resistance in cancer, only recently has the role of P‐gp expressed in normal tissues as a determinant of drug pharmacokinetics and pharmacodynamics been examined. P‐glycoprotein is present in organ systems that influence drug absorption (intestine), distribution to site of action (central nervous system and leukocytes), and elimination (liver and kidney), as well as several other tissues. Many marketed drugs inhibit P‐gp function, and several compounds are under development as P‐gp inhibitors. Similarly, numerous drugs can induce P‐gp expression. While P‐gp induction does not have a therapeutic role, P‐gp inhibition is an attractive therapeutic approach to reverse multidrug resistance. Clinicians should recognize that P‐gp induction or inhibition may have a substantial effect on the pharmacokinetics and pharmacodynamics of concomitantly administered drugs that are substrates for this transporter.

Keywords

P-glycoproteinPharmacokineticsPharmacologyPharmacodynamicsTransporterMultiple drug resistanceDrugATP-binding cassette transporterMedicineDrug resistanceBiologyBiochemistryGene

Affiliated Institutions

Related Publications

Publication Info

Year
2001
Type
review
Volume
21
Issue
7
Pages
778-796
Citations
219
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

219
OpenAlex

Cite This

Christopher Matheny, Matthew W. Lamb, Kim L. R. Brouwer et al. (2001). Pharmacokinetic and Pharmacodynamic Implications of P‐glycoprotein Modulation. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy , 21 (7) , 778-796. https://doi.org/10.1592/phco.21.9.778.34558

Identifiers

DOI
10.1592/phco.21.9.778.34558